Can leukemia-derived dendritic cells generate antileukemia immunity?

References

• Ohminam IH, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood95(1), 286–293 (2000).
   Google Scholar
• Azuma T, Makita M, Ninomiya K et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br. J. Haematol.116(3), 601–603 (2002).
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res.59(11), 2675–2681 (1999).
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res.61(18), 6846–6850 (2001).
   PubMed Web of Science ®Google Scholar
• Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood96(4), 1480–1489 (2000).
   PubMed Web of Science ®Google Scholar
• Gaiger A, Carter L, Greinix H et al. WT1-specific serum antibodies in patients with leukemia. Clin. Cancer Res.7(3 Suppl.), 761s–765s (2001).
   PubMedGoogle Scholar
• Savage P, Gao L, Vento K et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood103(12), 4613–4615 (2004).
   PubMedGoogle Scholar
• Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J. Immunol.164(4), 1873–1880 (2000).
   PubMed Web of Science ®Google Scholar
• Mailander V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia18(1), 165–166 (2004).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101(38), 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood88(7), 2450–2457 (1996).
   PubMed Web of Science ®Google Scholar
• Brugger W, Schneider A, Schammann T et al. Dendritic cell-based vaccines in patients with hematological malignancies. Ann. NY Acad. Sci.938, 359–362; discussion 362–353 (2001).
   Google Scholar
• Greiner J, Ringhoffer M, Simikopinko O et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp. Hematol.28(12), 1413–1422 (2000).
   PubMed Web of Science ®Google Scholar
• Boyer MW, Vallera DA, Taylor PA et al. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood89(9), 3477–3485 (1997).
   PubMed Web of Science ®Google Scholar
• Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood92(5), 1677–1684 (1998).
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol.9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol.18, 767–811 (2000).
   PubMed Web of Science ®Google Scholar
• O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood104(8), 2235–2246 (2004).
   PubMed Web of Science ®Google Scholar
• Young JW, Steinman RM. The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells14(4), 376–387 (1996).
   PubMed Web of Science ®Google Scholar
• Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J. Immunol.154(11), 5851–5861 (1995).
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med.183(1), 317–322 (1996).
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med.1(12), 1297–1302 (1995).
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med.183(1), 283–287 (1996).
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature392(6671), 86–89 (1998).
   PubMed Web of Science ®Google Scholar
• Spisek R, Chevallier P, Morineau N et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res.62(10), 2861–2868 (2002).
   PubMed Web of Science ®Google Scholar
• O’Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immun.52(6), 387–395 (2003).
   PubMed Web of Science ®Google Scholar
• Hirst WJ, Buggins A, Darling D et al. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther.4(7), 691–699 (1997).
   PubMed Web of Science ®Google Scholar
• Hirano N, Takahashi T, Azuma M et al. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Hum. Gene Ther.8(11), 1375–1384 (1997).
   PubMed Web of Science ®Google Scholar
• Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia16(9), 1645–1654 (2002).
   Google Scholar
• Orleans-Lindsay JK, Deru A, Craig JI, Prentice HG, Lowdell MW. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex vivo generation of CTL for immunotherapy. Clin. Exp. Immunol.133(3), 467–475 (2003).
   Google Scholar
• Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br. J. Haematol.129(3), 340–349 (2005).
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Kato Y et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res.28(12), 1303–1312 (2004).
   Google Scholar
• Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immun.51(6), 299–310 (2002).
   PubMed Web of Science ®Google Scholar
• Narita M, Takahashi M, Liu a et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp. Hematol.29(6), 709–719 (2001).
   PubMed Web of Science ®Google Scholar
• Mohty M, Isnardon D, Blaise D et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia16(11), 2267–2274 (2002).
   PubMed Web of Science ®Google Scholar
• Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur. J. Immunol.29(8), 2567–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Choudhury BA, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood93(3), 780–786 (1999).
   PubMed Web of Science ®Google Scholar
• Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immuother.24(7), 685–693 (2005).
   Google Scholar
• Houtenbos I, Westers TM, Ossenkoppele GJ, Van de Loosdrecht AA. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica91(3), 348–355 (2004).
   Google Scholar
• Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by ‘leukemic dendritic cells’ derived from blast cells in acute myeloid leukemia. Blood97(9), 2764–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Westers TM, Stam AG, Scheper RJ et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol. Immun.52(1), 17–27 (2003).
   PubMed Web of Science ®Google Scholar
• Robinson SP, English N, Jaju R et al. The in-vitro generation of dendritic cells from blast cells in acute leukaemia. Br. J. Haematol.103(3), 763–771 (1998).
   PubMed Web of Science ®Google Scholar
• Woiciechowsky A, Regn S, Kolb HJ, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia15(2), 246–255 (2001).
   PubMed Web of Science ®Google Scholar
• Cignetti A, Bryant E, Allione B et al. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood94(6), 2048–2055 (1999).
   PubMed Web of Science ®Google Scholar
• Cignetti A, Vallario A, Roato I et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J. Immunol.173(4), 2855–2865 (2004).
   PubMedGoogle Scholar
• Houtenbos I, Westers TM, Stam AG et al. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol. Immun.52(7), 455–462 (2003).
   PubMed Web of Science ®Google Scholar
• Waclavicek M, Berer A, Oehler L et al. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br. J. Haematol.114(2), 466–473 (2001).
   PubMed Web of Science ®Google Scholar
• Koski GK, Schwartz GN, Weng DE et al. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood94(4), 1359–1371 (1999).
   PubMed Web of Science ®Google Scholar
• Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia16(1), 84–93 (2002).
   PubMed Web of Science ®Google Scholar
• Vereecque R, Saudemont A, Depil S et al. Efficient generation of antileukemic autologous T cells by short-term culture and γ-irradiation of myeloid leukemic cells. Cancer Immunol. Immun.53(9), 793–798 (2004).
   Google Scholar
• Saudemont A, Corm S, Wickham T, Hetuin D, Quesnel B. Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-α. Mol. Ther.11(6), 950–959 (2005).
   Google Scholar
• Westers TM, Houtenbos I, Snoijs NC, Van de Loosdrecht AA, Ossenkoppele GJ. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity. Leukemia19(7), 1270–1272 (2005).
   Google Scholar
• Kufner S, Zitzelsberger H, Kroell T et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand. J. Immunol.62(1), 86–98 (2005).
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja M, Ayala E, Lindner I et al. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol. Immun.54(1), 25–36 (2005).
   Google Scholar
• Houtenbos I, Westers TM, De Gruijl TD et al. TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells. Leukemia18(6), 1149–1153 (2004).
   Google Scholar
• Li L, Giannopoulos K, Reinhardt P et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int. J. Oncol.28(4), 855–861 (2006).
   PubMed Web of Science ®Google Scholar
• Roddie H, Klammer M, Thomas C et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br. J. Haematol.133(2), 152–157 (2006).
   PubMed Web of Science ®Google Scholar